Rare Disease Consulting

Rare Disease Consulting (RDC) is a Greek micro-SME specialising in health economics, Health Technology Assessment (HTA), and real-world evidence for rare and ultra-rare diseases. The company builds on more than 15 years of international experience in health economics and outcomes research, with a dedicated focus on rare diseases since 2016.

RDC aims to support Horizon Europe and ERDERA consortia by evaluating the clinical, economic, and societal value of diagnostics, therapies, and care models in small-population settings. Its expertise includes health economic and HTA modelling for cost-effectiveness and long-term outcomes, as well as burden-of-illness assessment and analysis of resource use across care pathways.

RDC’s work focuses on understanding long-term affordability, feasibility, and health-system impact of health interventions in rare-disease and other small-population or highly-uncertainty research settings, taking into account clinical outcomes, patient-centred measures, and the specific evidence challenges associated with and heterogeneous populations.

Beyond technical analysis, RDC brings a strong conceptual understanding of economic and evidence-generation challenges in small and highly specialised rare-disease markets. This perspective supports research projects in addressing not only effectiveness, but also value, affordability, and longer-term system implications.

RDC is interested in joining Horizon Europe Cluster Health proposals as a consortium partner, contributing health economic analysis, HTA, and impact-related work packages, and collaborating closely with academic, clinical, SME, and patient-organisation partners involved in rare-disease research and innovation.